Ultragenyx Pharmaceutical (NASDAQ:RARE) Cut to “Neutral” at The Goldman Sachs Group

The Goldman Sachs Group downgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a buy rating to a neutral rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage currently has $25.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $61.00.

A number of other brokerages also recently issued reports on RARE. Wells Fargo & Company cut their price objective on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday, December 30th. Canaccord Genuity Group decreased their target price on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. Robert W. Baird lowered their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Guggenheim dropped their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, January 5th. Finally, Wedbush reissued a “neutral” rating and issued a $25.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $60.47.

Ultragenyx Pharmaceutical Stock Up 0.8%

NASDAQ RARE opened at $20.00 on Tuesday. The company has a 50-day moving average price of $22.44 and a 200-day moving average price of $28.18. Ultragenyx Pharmaceutical has a 52 week low of $18.29 and a 52 week high of $42.37. The firm has a market capitalization of $1.93 billion, a P/E ratio of -3.42 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The company had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.Ultragenyx Pharmaceutical’s revenue for the quarter was up 25.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.39) earnings per share. As a group, equities research analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Activity

In related news, EVP Karah Herdman Parschauer sold 8,135 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $185,478.00. Following the completion of the sale, the executive vice president owned 76,346 shares in the company, valued at approximately $1,740,688.80. This trade represents a 9.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Eric Crombez sold 7,029 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $160,261.20. Following the sale, the executive vice president directly owned 76,301 shares in the company, valued at $1,739,662.80. This trade represents a 8.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 104,958 shares of company stock valued at $2,394,858 in the last three months. 5.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds have recently modified their holdings of RARE. Vanguard Group Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company’s stock worth $236,068,000 after acquiring an additional 131,087 shares during the last quarter. State Street Corp grew its stake in Ultragenyx Pharmaceutical by 16.5% during the fourth quarter. State Street Corp now owns 4,303,046 shares of the biopharmaceutical company’s stock valued at $98,970,000 after acquiring an additional 610,559 shares in the last quarter. Wellington Management Group LLP increased its holdings in Ultragenyx Pharmaceutical by 26.6% in the 4th quarter. Wellington Management Group LLP now owns 2,461,910 shares of the biopharmaceutical company’s stock valued at $56,624,000 after acquiring an additional 516,781 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Ultragenyx Pharmaceutical by 614.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after acquiring an additional 1,864,164 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Ultragenyx Pharmaceutical by 16.3% in the 4th quarter. Geode Capital Management LLC now owns 1,838,208 shares of the biopharmaceutical company’s stock worth $42,287,000 after purchasing an additional 257,701 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Truist upgraded Ultragenyx to “strong‑buy,” a supportive catalyst that can attract buyers and provide near‑term technical support. Truist upgrade (Zacks)
• Negative Sentiment: Goldman Sachs downgraded RARE to “Neutral” (coverage widely reported), a move cited in press accounts that coincided with the stock hitting a 12‑month low in some outlets — weighing on investor sentiment and downward pressure from institutional analysts. Goldman Sachs downgrade
• Negative Sentiment: Multiple law firms and shareholder‑claim services have filed or publicized securities class‑action notices and are soliciting lead‑plaintiff applicants for alleged misstatements during the Aug. 3, 2023–Dec. 26, 2025 class period; the April 6, 2026 lead‑plaintiff deadline is being highlighted repeatedly — this increases legal uncertainty, potential settlement risk, and headline volatility. Representative notices: Rosen Law Firm / Newsfile and Pomerantz (PR Newswire). Rosen Law Firm notice Pomerantz notice

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.